CA Patent

CA2795550C — Solid dosage formulations of an orexin receptor antagonist

Assigned to Merck Sharp and Dohme LLC · Expires 2020-03-24 · 6y expired

What this patent protects

The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.

USPTO Abstract

The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.

Drugs covered by this patent

Patent Metadata

Patent number: CA2795550C
Jurisdiction: CA
Classification: —
Expires: 2020-03-24
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.